---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-005117"
form_type: "8-K"
ticker: "CERS"
cik: "0001020214"
company_name: "CERUS CORP"
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:10:09.836081+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cerus reports record preliminary Q4/FY2021 product revenue, guides 2022 up 20-25%

## Summary
- Q4 2021 preliminary product revenue $39.9M, up 41% YoY from $28.2M.
- Full-year 2021 preliminary product revenue $130.9M, above guidance of $127-129M.
- 2022 product revenue guidance $157-164M, representing 20-25% growth vs. 2021.
- More than half of U.S. platelets now treated with INTERCEPT on a run-rate basis.
- Nationwide launch of INTERCEPT Fibrinogen Complex after first BLA approval for Gulf Coast blood center.

## SEC filing metadata
- accession: 0001193125-22-005117
- form_type: 8-K
- ticker: CERS
- cik: 0001020214
- company_name: CERUS CORP
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1020214/000119312522005117/0001193125-22-005117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1020214/000119312522005117/d286874d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-005117
- JSON: https://secwatch.observer/filing/0001193125-22-005117.json
- Plain text: https://secwatch.observer/filing/0001193125-22-005117.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.